3,4-Dihydroxybenzeneacetic acid
|
Basic information |
| Metabolite name | 3,4-Dihydroxybenzeneacetic acid |
 | HMDB0001336 |
 |
C01161 |
 |
547 |
| Synonyms | DOPAC; |
| No. of studies | 10 |
|
Basic information |
| Metabolite name | 3,4-Dihydroxybenzeneacetic acid |
| HMDB0001336 |
|
C01161 |
|
547 |
| Synonyms | DOPAC; |
| No. of studies | 10 |
|
Relationship between 3,4-Dihydroxybenzeneacetic acid and depression (count: 10) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | sertraline-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M522 | Type2 | CUMS + NaP group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M574 | Type1 | CMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M574 | Type1 | CMS + n-3 PUFA deficiency group vs. control + n-3 PUFA deficiency group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M581 | Type1 | CUMS group vs. control group | Hypothalamus | Sprague-Dawley rat | Down |
| Study M581 | Type2 | CUMS + high dose of S. chinensis group vs. CUMS group | Hypothalamus | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type1 | CUMS + high dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M732 | Type2 | CUMS + low dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M732 | Type2 | CUMS + middle dose of propionate group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Up |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Down |
| Study M994 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M994 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M994 | Type2 | CUMS + Uncaria rhynchophylla extract group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |